LGC Biosearch Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

LGC Biosearch Technologies, founded in 1996, is a key supplier in the genomics tools and diagnostics sector, operating as part of the larger LGC group. The company provides end-to-end solutions from oligonucleotide design and synthesis to commercial-scale manufacturing of critical reagents for PCR, sequencing, and nucleic acid therapeutics. Its core strengths lie in its extensive product catalog, proprietary technologies like PrimeMax siRNA CPG and sbeadex kits, and a strong commitment to quality under ISO and GMP standards. It supports diverse applications in infectious disease, oncology, agriculture, and research.

Genetics & Genomics

Technology Platform

Suite of nucleic acid technologies including PrimeMax siRNA CPG for optimized oligonucleotide synthesis, sbeadex magnetic bead-based purification, PCR Forge assay design software, and expertise in oligo modifications and enzyme supply.

Opportunities

Significant growth is driven by the expanding market for RNA therapeutics, requiring high-quality synthesis reagents like its PrimeMax CPG.

The continued globalization and sophistication of molecular diagnostics, especially in oncology and infectious disease, create sustained demand for its probe/primer design services and GMP-manufactured oligos.

Agricultural genomics represents another high-growth vertical for its sample prep and genotyping tools.

Risk Factors

Faces intense competition from larger, diversified life science tool companies and agile niche players.

Technological shifts away from PCR-based methods or disruptive synthesis technologies could erode demand for core products.

Regulatory and supply chain dependencies pose operational risks to its manufacturing and customer support model.

Competitive Landscape

Operates in a highly competitive market dominated by giants like Thermo Fisher Scientific and Merck, who offer broad portfolios. Competes with pure-play oligo synthesis companies (e.g., Integrated DNA Technologies) and specialized reagent providers. Differentiation is achieved through deep technical expertise in modifications, high-quality GMP manufacturing, and integrated software and service offerings.

More companies in RNA Therapeutics (non-mRNA) →More companies in Denmark →